Press releases How it works Pricing Alert the newsroom

Sign in Publish a press release

Press releasesCompany announcements, live How it worksPublish in three steps PricingFree, or Pro at €69 excl. VAT per month

Alert the newsroomShare information without being identified

Publish a press release Sign in

Search Clarsource

Company, SIREN, topic or press release title

Loading…

Press releases from French companies and institutions, published by themselves and reviewed by our newsroom.

Publish a press release

Press releases

All press releases Fundraising Investments Organizations

Publish

How it works Pricing Companies Startups Institutions PR agencies All solutions

Use

Journalists Media partners Analysts and investors Developers and AI API documentation Clardot, the business newspaper ↗

Resources

Write a press release Send a press release Press release templates Examples by announcement type Online newsroom All guides

Trust

Alert the newsroom Editorial policy Report an announcement Reuse by AI

© 2026 FinadoryLegal notice Issuer terms Terms of sale PrivacyContact

Unclaimed pageCreated automatically from 4 public press releases and the French national business register. The organisation has not yet approved it.

OI

OSE IMMUNOTHERAPEUTICS

SIREN 479 457 715Activités scientifiques et techniquesNANTES, 44

Follow on Clardot

4announcements published
since October 2026

4in the last 12 months
over the period

Announcements visible on the feed

A detailed breakdown by type will follow as soon as the taxonomy allows.

Are you OSE IMMUNOTHERAPEUTICS?

Claim the page to publish your announcements directly and correct those taken from public sources.

Verified issuer badge on every announcement
Logo, description and press contact
Track your publications from the issuer space

Free. Checked by a Clarsource admin. About 2 minutes to submit the request.

Announcements

4

19/10/2026OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatiqueInformations réglementées continues — 19 octobre 2026 19/10/2026OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung CancerInformations réglementées continues — 19 octobre 2026 15/10/2026OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare ConferenceInformations réglementées continues — 15 octobre 2026 15/10/2026OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare ConferenceInformations réglementées continues — 15 octobre 2026

Legal identity

National register

Registered name: OSE IMMUNOTHERAPEUTICS
SIREN: 479 457 715
SIRET: 479 457 715 00056
NAF code: 72.11Z, Activités scientifiques et techniques
VAT: FR24479457715
Registered office: 44200, NANTES

Follow OSE IMMUNOTHERAPEUTICS

Get notified of upcoming announcements and articles that mention the company.

Follow on Clardot